Physician profile
John Perrotti
NPI 1386729648
$2,482.76
in general payments reported to CMS, 2019-2025
11 companies · $90.42 in 2025
The $90.42 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2021: $65.02 · 2022: $465 · 2023: $180 · 2024: $21.78 · 2025: $90.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222 · Consulting Fee: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.01 |
| Consulting Fee | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,535.25 | 2019 | |
| Becton, Dickinson and Company | $450.00 | 2022 | |
| Kci USA, INC. | $125.00 | 2019 | |
| Medtronic, INC. | $120.00 | 2021-2023 | Surgipro Ll |
| Janssen Biotech, INC. | $67.39 | 2022-2025 | Tremfya |
| Genzyme Corporation | $53.03 | 2023 | |
| Davol INC. | $38.51 | 2025 | Arista |
| Amgen INC. | $32.55 | 2023 | Otezla |
| Incyte Corporation | $24.23 | 2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $21.78 | 2024 | Dupixent |
| Stryker Corporation | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Perrotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.